These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19280612)

  • 1. Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503.
    Thevis M; Beuck S; Thomas A; Kortner B; Kohler M; Rodchenkov G; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Apr; 23(8):1139-46. PubMed ID: 19280612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for the calstabin-ryanodine receptor complex stabilizers JTV-519 and S-107 in doping control analysis.
    Thevis M; Beuck S; Thomas A; Kohler M; Schlörer N; Vajiala I; Schänzer W
    Drug Test Anal; 2009 Jan; 1(1):32-42. PubMed ID: 20355157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis.
    Thevis M; Kohler M; Maurer J; Schlörer N; Kamber M; Schänzer W
    Rapid Commun Mass Spectrom; 2007; 21(21):3477-86. PubMed ID: 17985352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes.
    Höppner S; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electron ionization mass spectrometry of the ryanodine receptor-based Ca(2+)-channel stabilizer S-107 and its implementation into routine doping control.
    Thevis M; Beuck S; Thomas A; Fusshöller G; Sigmund G; Schlörer N; Rodchenkov G; Schäfer M; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Aug; 23(15):2363-70. PubMed ID: 19575395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Thevis M; Kohler M; Thomas A; Schlörer N; Schänzer W
    Rapid Commun Mass Spectrom; 2008 Aug; 22(16):2471-8. PubMed ID: 18634123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis.
    Thevis M; Thomas A; Kohler M; Beuck S; Möller I; Schäfer M; Rodchenkov G; Yin S; Loo JA; Geyer H; Schänzer W
    Eur J Mass Spectrom (Chichester); 2010; 16(3):301-12. PubMed ID: 20530837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for two selective androgen receptor modulators using gas chromatography-mass spectrometry in doping control analysis.
    Thevis M; Kohler M; Schlörer N; Fusshöller G; Schänzer W
    Eur J Mass Spectrom (Chichester); 2008; 14(3):153-61. PubMed ID: 18708695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
    Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
    Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes.
    Thevis M; Kamber M; Schänzer W
    Rapid Commun Mass Spectrom; 2006; 20(5):870-6. PubMed ID: 16470709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
    Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of N-desmethyl- and N-bisdesmethyl metabolites of Sibutramine in doping control analysis using liquid chromatography-tandem mass spectrometry.
    Thevis M; Sigmund G; Schiffer AK; Schänzer W
    Eur J Mass Spectrom (Chichester); 2006; 12(2):129-36. PubMed ID: 16723754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach.
    Guddat S; Solymos E; Orlovius A; Thomas A; Sigmund G; Geyer H; Thevis M; Schänzer W
    Drug Test Anal; 2011; 3(11-12):836-50. PubMed ID: 22135086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doping control analysis of metamfepramone and two major metabolites using liquid chromatography-tandem mass spectrometry.
    Thevis M; Sigmund G; Thomas A; Gougoulidis V; Rodchenkov G; Schänzer W
    Eur J Mass Spectrom (Chichester); 2009; 15(4):507-15. PubMed ID: 19661559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.
    Knoop A; Krug O; Vincenti M; Schänzer W; Thevis M
    Eur J Mass Spectrom (Chichester); 2015; 21(1):27-36. PubMed ID: 25906032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometric studies on the in vitro generated metabolites of SIRT1 activating drugs for doping control purposes.
    Höppner S; Schänzer W; Thevis M
    J Mass Spectrom; 2013 Jul; 48(7):830-43. PubMed ID: 23832939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product.
    Thevis M; Geyer H; Kamber M; Schänzer W
    Drug Test Anal; 2009 Aug; 1(8):387-92. PubMed ID: 20355219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes.
    Beuck S; Schänzer W; Thevis M
    J Mass Spectrom; 2011 Feb; 46(2):112-30. PubMed ID: 21254313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry.
    Thevis M; Krug O; Schänzer W
    J Mass Spectrom; 2006 Mar; 41(3):332-8. PubMed ID: 16421876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.